Cingulate FY26 Q1 net loss widens 141.7% to $9.31 million

Cingulate

Cingulate

CING

0.00
  • Cingulate posted a net loss of USD 9.31 million for the quarter ended March 31, 2026, widening 141.7% from a year earlier.
  • Operating loss widened to USD 7.92 million, while general and administrative expense more than doubled to USD 5.74 million.
  • Research and development expense edged down 1.8% to USD 2.18 million, while interest and other expense widened to USD 537,000.
  • Cash and cash equivalents totaled USD 25.9 million as of March 31, with funding expected to last into early 2027; net cash used in operating activities was USD 6.91 million.
  • FDA set a May 31, 2026 PDUFA target action date for CTx-1301; NDA review included additional CMC information requests, while launch planning advanced via Indegene with field support through IQVIA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022884), on May 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.